Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Carboplatin + TAK-243|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|TAK-243||MLN7243||TAK-243 (MLN7243) is an inhibitor that selectively targets the ubiquitin activating enzyme, UBA1, which may result in inhibition of ubiquitination related processes such as cell cycle progression, apoptotic regulation, and DNA damage response (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A164).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Carboplatin + TAK-243||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of Paraplatin (carboplatin) and TAK-243 (MLN7243) resulted in synergistic and additive effects, demonstrating anti-tumor activity in xenograft tumor models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A164).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|